Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121925 · ClinicalTrials.gov registry record
Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- 227
- Enrollment target
NCT02121925: Clinical Trial study, sponsored by Myriad Genetic Laboratories.
NCT02121925 is a clinical trial that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 227 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02121925 was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- 227 participants
- Enrollment target
Study Summary
This registry is intended to measure the effect of myPlan Lung Cancer™ test has on treatment decisions of Surgeons when added to standard clinical-pathological parameters in patients with early stage NSCLC.The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006).This registry is specific to Surgeons (ONC003). Outcomes measures on lung cancer relapse and death from any cause will be collected.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02121925
The ClinicalTrials.gov registry entry for NCT02121925 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myriad Genetic Laboratories, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02121925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02121925 about?
NCT02121925 is a clinical study titled "Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up". This registry is intended to measure the effect of myPlan Lung Cancer™ test has on treatment decisions of Surgeons when added to standard clinical-pathological parameters in patients with early stage NSCLC.The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and ...
What is the current status of trial NCT02121925?
This trial is currently terminated. The enrollment target is 227 participants. The study started on 2014-05. Estimated completion is 2017-07-31.
Who is sponsoring clinical trial NCT02121925?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.